Canada · Advertising framework
Email, SMS and direct-message marketing for digital health products in Canada
General market orientation, not campaign clearance. Research scope and dates
Product and service rules
Start with Canadian market authorisation
Regulator guidance
Advertising eligibility depends on the product’s Canadian regulatory status and authorised uses. Health Canada describes independent preclearance as generally voluntary, with specific exceptions such as opioid advertising; do not label every campaign as legally subject to mandatory preclearance.
Sources: Advertising requirements for drugs and medical devices
Review the exact health-product classification
Regulator guidance
For a Class II, III or IV device, Medical Devices Regulations section 27 generally requires the manufacturer’s device licence or amended licence before advertising for sale. A limited catalogue exception requires the specified clear warning; it is not a general consumer-campaign exemption.
Separate the device licence from establishment licensing and verify the advertised model and intended use. A laboratory service or health app also needs its own classification assessment.
Sources: Advertising requirements for drugs and medical devices; Distinction between advertising and other activities: legislative and regulatory provisions · Health Canada legislative excerpts: Medical Devices Regulations section 27
Channel rules
Check the complete consumer-facing message
Regulator guidance
Competition Act provisions address materially false or misleading promotion of products, services and business interests. The assessment considers literal meaning and general impression, including images and omitted conditions. Review professional titles, claimed outcomes and conditional prices with the same care as the headline.
Sources: False or misleading representations
Check CASL before sending commercial electronic messages
Regulator guidance
Commercial email and text messages generally need an express or qualifying implied consent basis, identification information and a working unsubscribe mechanism. Document the applicable conditions and expiry of any implied consent; a message asking for consent can itself be commercial.
Sources: Canada’s anti-spam legislation: FAQs
Calculate implied-consent expiry for each recipient
Regulator guidance
For the existing-business-relationship route, qualifying purchases generally support two years of implied consent; qualifying enquiries or applications support six months. A qualifying written contract may support consent while in force and for two years after expiry. These periods do not replace the conditions of the particular route. Express consent has no fixed expiry but can be withdrawn; honour unsubscribe requests within ten business days and keep proof of the basis used.
Sources: CASL implied-consent periods
Quebec: review French content and signage separately
Regulator guidance
Applies when: Quebec commercial-language rules apply to the business and execution.
Businesses operating in Quebec must provide French commercial publications, including a complete French website and French social-media content, subject to applicable exceptions. Public signage and commercial advertising have a distinct French-predominance regime. Review the rules effective from 1 June 2025 for trademarks and business names on signage; a bilingual website alone does not resolve an exterior sign.
Sources: French-language rights in commerce; Business names and trademarks on signage
Separate promotional and service messages
Editorial recommendation
Review the rules for the actual delivery method: email, SMS and private social messages are not interchangeable. Keep the relevant permission record, accurate sender details and a working suppression process.
A public email address is not unrestricted marketing permission
Regulator guidance
CRTC describes a narrow conspicuous-publication route: there must be no statement refusing commercial messages and the message must relate to the recipient’s business role, functions or duties. Document the actual basis instead of treating a scraped address as blanket consent.
A stop request must be respected within ten business days regardless of the original consent type. Keep the contact-permission assessment separate from health-data and professional restrictions.
Campaign workflow
Digital Health Products: prepare the review
Editorial recommendation
Classify each software function separately: lifestyle, medical software or delivery of care. Link accuracy and clinical outcome claims to the advertised software version and population. Review tracking and marketing data flows separately from permission to provide care.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Classify each software function separately: lifestyle, medical software or delivery of care.
- Link accuracy and clinical outcome claims to the advertised software version and population.
- Review tracking and marketing data flows separately from permission to provide care.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- Ontario physician and dental guidance and Quebec commercial-language requirements are documented. Other provinces/territories, pharmacy rules and health-information statutes remain outside this targeted review. CASL permission does not itself authorise use of clinical records for marketing.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
A digital-health offer promoted by email, SMS and direct messages in Canada may combine a lifestyle function, medical software and a clinical service. Identify each advertised function and software version, then review clinical claims and the use of personal data separately.
Email, SMS and private platform messages can follow different permission rules. Identify the delivery technology and the recipient relationship, then review the promotional content and withdrawal process separately.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Federal health-product and competition-law baseline; provinces, territories and Quebec language requirements need local checks. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- Advertising requirements for drugs and medical devices
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Distinction between advertising and other activities: legislative and regulatory provisions
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- False or misleading representations
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Canada’s anti-spam legislation: FAQs
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- CASL implied-consent periods
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- French-language rights in commerce
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- Business names and trademarks on signage
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- CRTC — CASL guidance on implied consent
Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.
From framework to action
Local expertise in Canada
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Canada.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.
